Apologies About the Pharmababble Feed

I had some technical problems with the new site layout and my feed was spewing press releases (i.e.; i didn’t know what I was doing and screwed something up).
Everything should be back to normal now though.  Thanks for reading.
Eben

Share and Enjoy:

Biotech Committed Equity Financing Facility

I can’t tell you why this seems to be the year of CEFFs (committed equity financing facility) but it can’t be argued otherwise. As you can see from the google news hist-trend-o-graph, press releases with CEFF in them are on pace to hit an all time high in 2008.

Basically, private investment firms (Kingsbridge Capital [...]

Biomed Funding Roudup: Week Ending 8.1.08

ReGen Biologics Closes $2.5 Million Private Placement and Announces New 510(k) Submission to the FDA
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products. The recently filed 510(k) seeks clearance of a collagen scaffold device for reinforcement and repair of meniscus tissue.
Biolex Therapeutics Adds $10.5 Million in [...]

PTC Inks $437M Gene Therapy Deal With Genzyme

Image via Wikipedia
Talk about a good week for PTC.
A day after announcing the Cystic Fibrosis Foundation is dropping $25M on PTC124 (PTC’s novel oral therapy in late-stage development for the treatment of genetic disorders due to nonsense mutations) and funding the phase 2 trial, Genzyme and PTC Therapeutics announced an exclusive global collaboration to develop [...]

On Vacation Until 7.16

Photo from **FLUK** on Flickr used under a Creative Commons License

Share and Enjoy:

Secretive Agios Makes Splash with $33M Series A

Image via Wikipedia
Agios Pharmaceuticals, backed by heavy hitters: Third Rock, Flagship and ARCH venture groups, announced it has closed a hefty, $33M Series A financing round.
There is very little substance in the press release or on the Agios website about the company or the technology.
The basic gist though, has to do with modulating the metabolism [...]

Biopharm Closing Bell: 6.13.08

Top Movers

Generated 4 hours ago

Gainers (% price change)
Last Trade
Change
Mkt Cap

Sequenom, Inc.
SQNM
14.94
+2.10 (16.36%)
678.38M

Chindex Intl, Inc.
CHDX
16.32
+1.72 (11.78%)
203.22M

Helicos BioSciences Corp.
HLCS
4.96
+0.52 (11.71%)
103.84M

DexCom, Inc.
DXCM
8.00
+0.77 (10.65%)
235.80M

Bio-Imaging Tech, Inc.
BITI
7.25
+0.66 (10.02%)
103.33M

Losers (% price change)
 

Maxygen, Inc.
MAXY
3.49
-1.36 (-28.04%)
129.29M

MiddleBrook
MBRK
3.29
-0.31 (-8.61%)
184.26M

Cytori Therapeutics Inc.
CYTX
7.62
-0.57 (-6.96%)
198.91M

Javelin Pharmaceuticals
JAV
2.80
-0.19 (-6.35%)
137.47M

Cardica, Inc.
CRDC
9.26
-0.59 (-5.99%)
145.43M

Most Actives (dollar volume)
 

Pfizer Inc.
PFE
17.99
+0.26 (1.47%)
121.71B

Merck & Co., Inc.
MRK
35.53
+0.13 (0.37%)
76.27B

Johnson & Johnson
JNJ
66.27
+0.58 (0.88%)
186.76B

Bristol Myers Squibb Co.
BMY
20.12
+0.45 (2.29%)
39.83B

Gilead Sciences, Inc.
GILD
54.14
+1.41 (2.67%)
49.94B

Share and Enjoy:

Genentech and Symphogen Team Up For $330M

Image via Wikipedia

I try not to be biased, but it’s not too often I discuss danish biotech companies on this blog.  Today is different. We are having a full international day here at Pharmababble.  First the Daiichi news and now this release of a collaboration from Symphogen and Genentech.  
The specifics of the alliance are [...]

Random Question

When did the word “biotech” become synonymous with the words, “quick” and “nimble”?

Share and Enjoy:

Drug Development: From Discovery to NDA

Introduction
The time it takes from starting a program to selling a product can vary but is usually estimated to be around 10 years and the total cost associated with bringing a drug to market is widely cited to be at least $850 million. These numbers outline high stakes and whether you are an [...]

Biopharm Closing Bell: 6.6.08

Highlights:
Inspire up on positive phase 3 results in a cystic fibrosis trial

Have a great weekend.

Gainers (% price change)
Last Trade
Change
Mkt Cap

Inspire Pharmaceuticals,
ISPH
5.19
+1.34 (34.81%)
293.66M

MiddleBrook
MBRK
3.85
+0.50 (14.93%)
215.63M

Vision-Sciences, Inc.
VSCI
5.50
+0.60 (12.24%)
193.97M

Cardium Therapeutics Inc.
CXM
2.39
+0.16 (7.13%)
104.22M

Verenium Corporation
VRNM
2.27
+0.14 (6.57%)
144.48M

Losers (% price change)
 

ChemGenex Pharmaceuticals
CXSP
14.50
-2.76 (-15.99%)
179.65M

Sangamo Biosciences, Inc.
SGMO
9.45
-1.60 (-14.48%)
385.71M

Sucampo Pharmaceuticals,
SCMP
10.23
-1.18 (-10.34%)
426.94M

Alphatec Holdings, Inc.
ATEC
4.52
-0.47 (-9.42%)
214.26M

DURECT Corporation
DRRX
4.40
-0.45 (-9.28%)
326.24M

Most Actives (dollar volume)
 

Pfizer Inc.
PFE
17.96
-0.71 (-3.80%)
121.50B

Johnson & Johnson
JNJ
65.76
-1.20 (-1.79%)
185.32B

Merck & Co., Inc.
MRK
37.49
-1.40 (-3.60%)
80.47B

Wyeth
WYE
42.93
-1.57 (-3.53%)
57.24B

Eli Lilly & Co.
LLY
48.42
-1.04 (-2.10%)
55.05B

Share and Enjoy:

Biopharma Closing Bell: 6.5.08

Gainers (% price change)
Last Trade
Change
Mkt Cap

Tercica, Inc.
TRCA
8.80
+4.39 (99.55%)
453.94M

Sequenom, Inc.
SQNM
11.15
+1.82 (19.51%)
506.28M

XTL Biopharmaceuticals
XTLB
3.45
+0.47 (15.77%)
100.97M

Metabolix, Inc.
MBLX
13.23
+1.75 (15.24%)
300.68M

Cell Genesys, Inc.
CEGE
3.67
+0.47 (14.69%)
289.03M

Losers (% price change)
 

MiddleBrook
MBRK
3.35
-1.10 (-24.72%)
187.62M

Regeneron
REGN
15.35
-3.73 (-19.55%)
1.21B

MDS Inc. (USA)
MDZ
16.40
-1.95 (-10.63%)
2.01B

Elbit Imaging Ltd
EMITF
47.25
-3.16 (-6.27%)
1.20B

Novavax, Inc.
NVAX
2.86
-0.18 (-5.92%)
176.72M

Most Actives (dollar volume)
 

Pfizer Inc.
PFE
18.67
-0.13 (-0.69%)
126.31B

Johnson & Johnson
JNJ
66.96
+0.41 (0.62%)
188.71B

Merck & Co., Inc.
MRK
38.89
+0.72 (1.89%)
83.48B

Novartis AG (ADR)
NVS
53.01
+0.61 (1.16%)
120.52B

Teva Pharmaceutical
TEVA
45.98
+0.98 (2.18%)
37.34B

Share and Enjoy:

Guide to Financial Statements: Intro

The Basics
One of the first things you should do if you want to get into the business side of biotechnology is familiarize yourself with financial statements and basic accounting. Luckily, a degree in accounting or finance is not a prerequisite. There are no nested, partial-differential equations or partition functions involved, and in fact, [...]

Guide to Financial Statements: Balance Sheets

Balance Sheets
A balance sheet is comprised of detailed information about a company’s:

Assets: Things a company owns that have value (can be sold or used to make products that can be sold). This includes, manufacturing plants, equipment, inventory, cash and, importantly for biotech, intellectual property in the form of patent and trademarks.
Liabilities: Things a company [...]

Guide to Financial Statements: Income Statements

An income statement (or profit and loss / P&L) is the report that shows you how much revenue (sales) the company earned in a year and also shows the costs related to obtaining that revenue. Basically, the top line of the income statement has value of total sales while the bottom line is the [...]